Msd (norge) AS

DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases.

Taipei Medical University and MSD Taiwan have signed a groundbreaking Memorandum of Understanding to collaborate across six key areas, marking the first large-scale alliance between a global pharmaceutical company and a medical university in Taiwan.

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

The U.S. Court of Appeals for the Federal Circuit has affirmed that patent term extensions (PTE) for reissue patents should be calculated from the original patent's issue date, not the reissue date.

• A groundbreaking mRNA vaccine (mRNA-1647) demonstrates superior efficacy against cytomegalovirus infection in phase 3 clinical trials, offering new hope for preventing CMV transmission. • The global CMV infections market is projected to experience significant growth across seven major markets, with a diagnosed population of 111,000 cases reported in 2022. • Leading pharmaceutical companies including ModernaTX, Merck Sharp & Dohme, GlaxoSmithKline, and AlloVir are developing innovative therapies to address unmet needs in CMV treatment.

A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing treatments for Ewing Sarcoma, with multiple promising candidates in various clinical stages.

DelveInsight's latest report reveals over 55 companies actively developing 55+ pipeline drugs for Pulmonary Arterial Hypertension treatment, indicating robust research activity in this therapeutic area.

DelveInsight's latest pipeline report reveals over 55 pharmaceutical companies actively developing 60+ innovative drug candidates for schizophrenia treatment, indicating significant industry investment in addressing this serious mental illness.

• DelveInsight's comprehensive analysis identifies over 70 pharmaceutical companies actively developing 75+ pipeline drugs for advanced cervical cancer treatment. • AstraZeneca's Imfinzi (durvalumab) leads late-stage developments, currently in Phase III trials for locally advanced cervical cancer, building on its success in lung cancer treatment. • Key clinical trials include promising immunotherapy combinations, with Merck's pembrolizumab plus chemoradiotherapy and AstraZeneca's volrustomig studies scheduled for significant developments in 2025.

Lupin has been granted tentative FDA approval for its generic version of Janumet (sitagliptin and metformin hydrochloride) tablets, used to manage type 2 diabetes.